M. P. Dillon

发表

J. Gever, D. Cockayne, M. P. Dillon, 2006, Pflügers Archiv.

Inside the Mind of a Medicinal Chemist: The Role of Human Bias in Compound Prioritization during Drug Discovery

Meir Glick, John D. Coley, Peter S. Kutchukian, 2012, PloS one.

Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.

M. P. Dillon, M. Cox, Yipin Lu, 2015, ACS medicinal chemistry letters.

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.

M. P. Dillon, P. Atadja, Youzhen Wang, 2017, Journal of medicinal chemistry.

Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase.

M. P. Dillon, M. Lindvall, D. Bussiere, 2017, Journal of medicinal chemistry.

Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.

M. P. Dillon, R. Grotzfeld, Edward G. Lorenzana, 2019, ACS medicinal chemistry letters.

Muscarinic receptor ligands and their therapeutic potential.

M. P. Dillon, R. Eglen, S. Hegde, 1999, Current opinion in chemical biology.

Pharmadynamic (PD) & pharmacokinetic (PK) properties of AF‐219: first in class, selective, clinical P2X3 antagonist in development for chronic pain and related conditions

M. P. Dillon, A. Ford, Steven A Smith, 2013 .

Effect of YM-44781, YM-44778 and YM-49598, Novel Tachykinin Antagonists, in a Drug-Induced Bladder Contraction Model

M. P. Dillon, G. Stepan, A. Choppin, 2002, Pharmacology.

Extraction of active clonidine-displacing substance from bovine lung and comparison with clonidine-displacing substance extracted from other tissues.

M. P. Dillon, D. Nutt, N. Morgan, 1999, European journal of pharmacology.

Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates

Daniel S. Palacios, M. P. Dillon, T. Abrams, 2018, ACS medicinal chemistry letters.

N-(Quinuclidin-3-yl)-2-(1-methyl-1H-indol-3-yl)-2-oxo-acetamide: a high affinity 5-HT3 receptor partial agonist

M. P. Dillon, E. Wong, K. Bley, 1995 .

Application of the “trimethyl lock”1 to Ganciclovir, a pro-prodrug with increased oral bioavailability☆

M. P. Dillon, H. Maag, H. Cai, 1996 .

Enantioselective synthesis of monocerin and fusarentin ethers: antifungal and insecticidal fungal metabolites

M. P. Dillon, T. J. Simpson, J. Sweeney, 1992 .

The synthesis of isotopically labelled N-acetylcysteamine thioesters utilising a baker's yeast reduction in D2O

M. P. Dillon, T. J. Simpson, J. Sweeney, 1991 .

Enantioselective Synthesis of Monocerin and Fusarentin Ethers: Antifungal and Insecticidal Fungal Metabolites.

M. P. Dillon, T. J. Simpson, J. Sweeney, 1993 .

Synthetic and mechanistic studies on fungal metabolic pathways: A guide to fungicide design

M. P. Dillon, T. J. Simpson, T. M. Donovan, 1991 .

Total synthesis of (±)-byssochlamic acid

M. P. Dillon, James D White, R. Butlin, 1992 .

THE REGIOSELECTIVE OPENING OF 5-O-BENZYL-1,2:3,4-O-ISOPROPYLIDENE-D-PSICOFURANOSE WITH ORGANOSTANNANES

M. P. Dillon, H. Maag, Dawn M. Myszynski, 1995 .

Rearrangement reactions in 1-methyl-2-vinylsilacyclopropane

M. P. Dillon, I. Davidson, Michael P. Clarke, 1988 .

'Seeing through a glass darkly': casting light on imidazoline 'I' sites.

M. P. Dillon, D. Nutt, N. Morgan, 1998, Trends in pharmacological sciences.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

M. P. Dillon, P. Atadja, E. Li, 2022, Journal of medicinal chemistry.

Purinoceptors as therapeutic targets for lower urinary tract dysfunction

J. Gever, D. Cockayne, M. P. Dillon, 2006, British journal of pharmacology.

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.

W. Sellers, M. P. Dillon, Y. Mishina, 2020, Journal of medicinal chemistry.

Abstract 1943: PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition

Kedar S Vaidya, M. P. Dillon, M. Fischer, 2018, Experimental and Molecular Therapeutics.

Asymmetric synthesis of (+)-nemorensic acid— revision of the stereochemistry of the pyrrolizidine alkaloid nemorensine

M. P. Dillon, James D White, F. Stappenbeck, 1995 .

Asymmetric Synthesis of (+)-Nemorensic Acid - Revision of the Stereochemistry of the Pyrrolizidine Alkaloid Nemorensine.

M. P. Dillon, James D White, F. Stappenbeck, 1996 .

Isolation of RP-HPLC pure clonidine-displacing substance from NG108-15 cells.

M. P. Dillon, D. Nutt, A. Hudson, 2000, European journal of pharmacology.

Comparison of Crude Methanolic CDS Extracts from Various Tissues

M. P. Dillon, D. Nutt, A. Hudson, 1999, Annals of the New York Academy of Sciences.

Harmane and harmalan are bioactive components of classical clonidine-displacing substance.

E. Robinson, M. P. Dillon, D. Nutt, 2004, Biochemistry.

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

M. P. Dillon, Mallika Singh, E. Lees, 2017, Journal of medicinal chemistry.

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.

Joshua M. Korn, W. Sellers, F. Shen, 2018, Cancer research.

AF‐353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist

J. Gever, M. P. Dillon, G. Burnstock, 2010, British journal of pharmacology.

The discovery and development of gefapixant

J. Gever, M. P. Dillon, M. Kitt, 2021, Autonomic Neuroscience.

Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

J. Gever, M. P. Dillon, A. Ford, 2009, Bioorganic & medicinal chemistry letters.

Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

J. Gever, M. P. Dillon, A. Ford, 2009, Bioorganic & medicinal chemistry letters.

Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.

J. Gever, M. P. Dillon, A. Ford, 2005, Bioorganic & medicinal chemistry letters.

Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.

J. Gever, M. P. Dillon, A. Ford, 2010, Bioorganic & medicinal chemistry letters.

Discovery and Synthesis of a Novel and Selective Drug-Like P2X1 Antagonist.

J. Gever, M. P. Dillon, A. Ford, 2005 .

M. P. Dillon, Mallika Singh, E. Lees, 2017, Journal of medicinal chemistry.